Spring Bank Pharmaceuticals

The Company’s SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. The Company has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections.
Type
Public
HQ
Hopkinton, US
Founded
2002
Size (employees)
15 (est)
Spring Bank Pharmaceuticals was founded in 2002 and is headquartered in Hopkinton, US

Spring Bank Pharmaceuticals Office Locations

Spring Bank Pharmaceuticals has an office in Hopkinton
Hopkinton, US (HQ)
86 South St

Spring Bank Pharmaceuticals Data and Metrics

Spring Bank Pharmaceuticals Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(17.4 m)

EBIT (FY, 2016)

(19.4 m)

Market capitalization (23-May-2017)

113 m

Closing share price (23-May-2017)

12

Cash (31-Dec-2016)

10.7 m
Spring Bank Pharmaceuticals's current market capitalization is $113 m.
Numbers are in $, USDFY, 2016

R&D expense

14 m

General and administrative expense

5.7 m

Operating expense total

19.8 m

EBIT

(19.4 m)

Interest income

96 k

Net Income

(17.4 m)
Numbers are in $, USDFY, 2016

Cash

10.7 m

Inventories

840 k

Current Assets

25.6 m

PP&E

522 k

Accounts Payable

1.5 m

Current Liabilities

3.5 m

Additional Paid-in Capital

68.6 m

Retained Earnings

(51.5 m)

Total Equity

17 m
Numbers are in $, USDFY, 2016

Net Income

(17.4 m)

Depreciation and Amortization

118 k

Inventories

(527 k)

Accounts Payable

(812 k)

Cash From Operating Activities

(15.8 m)

Purchases of PP&E

(213 k)

Cash From Investing Activities

(6.5 m)

Cash From Financing Activities

28.7 m

Spring Bank Pharmaceuticals Market Value History

Spring Bank Pharmaceuticals Company Life and Culture

You may also be interested in